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Summary
Modification of specific Gram-negative bacterial cell envelope components, such as capsule, O-
antigen and lipid A, are often essential for the successful establishment of infection. Francisella
species express lipid A molecules with unique characteristics involved in circumventing host
defences, which significantly contribute to their virulence. In this study, we show that NaxD, a
member of the highly conserved YdjC superfamily, is a deacetylase required for an important
modification of the outer membrane component lipid A in Francisella. Mass spectrometry analysis
revealed that NaxD is essential for the modification of a lipid A phosphate with galactosamine in
Francisella novicida, a model organism for the study of highly virulent Francisella tularensis.
Significantly, enzymatic assays confirmed that this protein is necessary for deacetylation of its
substrate. In addition, NaxD was involved in resistance to the antimicrobial peptide polymyxin B
and critical for replication in macrophages and in vivo virulence. Importantly, this protein is also
required for lipid A modification in F. tularensis as well as Bordetella bronchiseptica. Since NaxD
homologues are conserved among many Gram-negative pathogens, this work has broad
implications for our understanding of host subversion mechanisms of other virulent bacteria.
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Mammalian host defences include multiple pathways for recognition of, and action against,
Gram-negative bacterial cell wall components including capsule, O-antigen and lipid A.
Accordingly, many such pathogens have evolved modifications of these structural elements
in order to evade host responses. The lipid A molecules of Francisella species have multiple
unique modifications, although the details of the pathways involved in generating these
alterations are still being elucidated.
Francisella tularensis is a Gram-negative intracellular pathogen and the causative agent of
tularaemia. Due to its extreme infectivity, high morbidity and mortality rates, history of
weaponization, and ease of aerosolization and dissemination, it is considered a category A
select agent (potential bioweapon) by the Centers for Disease Control and Prevention (CDC)
(Darling et al., 2002). Francisella novicida is a less virulent species that rarely causes disease
in humans but is frequently used as a laboratory model as it causes a tularaemia-like disease
in mice, is easily genetically manipulated, and is known to use many of the same virulence
determinants as F. tularensis (Titball and Petrosino, 2007). These include the Francisella
pathogenicity island (FPI), which is thought to encode a putative type VI secretion system,
oxidative stress resistance proteins, siderophores, and outer membrane lipid A modifications
that enable the bacteria to evade recognition and damage by host phagocytes (Bakshi et al.,
2006; Gunn and Ernst, 2007; Nano and Schmerk, 2007; Ramakrishnan et al., 2008; Honn et
al., 2012).
Francisella LPS has a unique lipid A moiety that is distinct from canonical lipid A structures
of other Gram-negative pathogens. For example, compared with the hexa-acylated lipid A
expressed by Escherichia coli, Francisella lipid A features only four acyl chains that are
longer than those of E. coli by as many as six carbons (Raetz and Whitfield, 2002; Trent,
2004; Raetz et al., 2009) (Fig. 1A and B). In addition, Francisella LPS lacks both the 4′ and
1 position distal phosphates (Raetz et al., 2009). Also unique to Francisella species, 70% of
the total lipid A in the outer membrane exists in a ‘free’ form that lacks the traditional Kdo,
core and O-antigen polysaccha-rides of complete LPS (Wang et al., 2006; Zhao and Raetz,
2010) (Fig. 1C). Unlike the lipid A of complete LPS, free lipid A retains the 1 position
phosphate that is further modified with a galactosamine residue.
As highly successful intracellular pathogens, Francisella species are able to utilize multiple
phagocytic and non-phagocytic cell types for replication (Fujita et al., 1993; Qin and Mann,
2006; Hall et al., 2007; 2008; Schulert et al., 2009). Entry into host macrophages often
occurs by a novel process involving the formation of unusually large and asymmetrical
pseudopod loops (Clemens and Horwitz, 2007). One to 3 h after uptake by phagocytes,
Francisella species escape the phagosome before replicating within the host cytosol.
However, many of the details of Francisella's intracellular life cycle are still unknown
(Clemens and Horwitz, 2007).
Although much progress has been made in understanding Francisella virulence mechanisms,
there are still many questions regarding how this pathogen is able to so effectively replicate
within host cells and cause disease. To begin to answer these questions, we performed a
genome-wide in vivo negative selection screen to identify genes required for pathogenesis
(Weiss et al., 2007). Next, we conducted an intracellular replication screen to determine
which of those genes were important specifically for replication in macrophages (Llewellyn
et al., 2011). FTN_0544 was identified in both of these screens. Although annotated as a
hypothetical protein of unknown function in the NCBI database, FTN_0544 belongs to the
YdjC superfamily of proteins. Interestingly, proteins belonging to this family are encoded by
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multiple Gram-negative pathogens including Bordetella bronchiseptica, Brucella abortus,
Coxiella burnetii and Legionella pneumophila.
In this study, we show that FTN_0544 is a deacetylase involved in the galactosamine
modification of Francisella's unique free lipid A molecules. We have thus renamed this
protein NaxD (N-acetylhexosamine deacetylase). Furthermore, we show that the action of
NaxD is required for resistance to the cationic antimicrobial peptide polymyxin B,
intracellular replication and virulence in vivo. Importantly, we have shown that the role of
this protein is conserved in human pathogenic F. tularensis, as well as B. bronchiseptica.
Since NaxD is highly conserved in numerous Gram-negative pathogens, this work has broad
implications for the elucidation of mechanisms of pathogenesis in other virulent bacteria.
Results
NaxD is a member of the YdjC superfamily of proteins
Although naxD is annotated as encoding a hypothetical protein in the NCBI database,
protein sequence analysis revealed that NaxD belongs to the YdjC superfamily. This family
is highly conserved, with over 3000 entries in the NCBI database. Homologues of NaxD are
encoded by numerous pathogens including B. bronchiseptica, B. abortus, L. pneumophila
and C. burnetii (Fig. 2A). While a member of this family from Bacillus stearothermophilus
had been putatively identified as a part of a cryptic cellobiose metabolism operon (Lai and
Ingram, 1993), another member from Thermus thermophilus, TTHB029, has been shown to
have structural similarity to a deacetylase from Streptococcus pneumoniae (Imagawa et al.,
2008). Structural analysis revealed a putative active site containing three potential catalytic
residues (Imagawa et al., 2008). Importantly, these residues are conserved among YdjC
superfamily proteins (Fig. 2B), suggesting that NaxD and other YdjC proteins may function
as deacetylases.
NaxD is required for F. novicida replication in macrophages and virulence in vivo
We originally identified naxD as being required for virulence in an in vivo genome-wide
negative selection screen (Weiss et al., 2007). In addition, we showed that this gene was
required for intracellular proliferation in a macrophage replication screen (Llewellyn et al.,
2011). Since both of these screens utilized transposon mutants, we wanted to ensure that the
observed phenotypes resulted from disruption of naxD and not unintended secondary
mutations. To do this, we generated an F. novicida naxD deletion mutant and a
complemented strain. The naxD mutant exhibited wild-type growth kinetics in both rich and
minimal media (Fig. S1). Macrophage replication experiments revealed that the naxD
mutant was unable to replicate in either RAW264.7 macrophages or primary murine bone
marrow-derived macrophages (BMM) (Fig. 3A and B). In fact, the level of attenuation of
the naxD mutant was similar to that of a previously characterized strain lacking a functional
copy of the gene encoding the virulence factor MglA, which is known to persist but not
replicate in macrophages (Baron and Nano, 1998). In addition, the naxD complemented
strain replicated to levels similar to wild-type. Given that Francisella must escape the
phagosome in order to replicate, we used fluorescence microscopy to measure escape
kinetics via colocalization of intracellular bacteria with the phagosomal marker LAMP-1
(Fig. S2). These experiments demonstrated that wild-type and naxD mutant F. novicida
escaped the phagosomes of BMM with similar kinetics, indicating that the mutant's
attenuation in macrophages is not due to a deficiency in phagosomal escape (Fig. S2).
Overall, these results show that NaxD is required for intracellular proliferation but not for
phagosomal escape.
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While our in vivo negative selection screen identified naxD as being important for virulence,
it did not provide quantitative data regarding the degree of attenuation of a naxD mutant. To
determine this, we performed competition experiments. Briefly, mice were infected with a
1:1 ratio of wild-type F. novicida and either the naxD deletion mutant or complemented
strain. Forty-eight hours post infection, the naxD mutant displayed an approximate 2.5 log
attenuation in the skin and a nearly 5 log attenuation in both the liver and spleen compared
with wild-type (Fig. 3C). All mutant phenotypes were restored to wild- type levels in the
complemented strain (Fig. 3C). To determine the consequence of the naxD mutant's
virulence defect, we infected mice with either the wild-type or mutant strain and monitored
survival. While mice infected with wild-type bacteria were moribund by 4 days after
infection, the mutant did not kill mice up to 28 days post infection (Fig. 3D). Taken
together, these data show that naxD is required for both replication in host macrophages and
virulence in vivo.
NaxD is involved in altering surface charge and resistance to polymyxin B
After validating the importance of NaxD in F. novicida infection of macrophages and mice,
our next aim was to determine the role of this protein in pathogenesis. To further
characterize the phenotypes of the naxD mutant, we subjected both wild-type and the
deletion mutant to different antimicrobials and compared the survival of each strain. While
the wild-type was unaffected at the concentrations tested, the mutant displayed dose-
dependent sensitivity to the cationic antimicrobial peptide polymyxin B (Fig. 4A), which
acts on Gram-negative bacteria by binding to the negatively charged lipid A component of
LPS (Morrison and Jacobs, 1976). Conversely, the mutant showed increased resistance to
the anionic detergent SDS (Fig. 4B) and displayed wild-type levels of sensitivity to the non-
ionic detergent Triton X-100 (Fig. 4C). The altered response of the mutant to charged
antimicrobials that act on the cell membrane suggested that NaxD might be involved in
altering the net charge of the bacterial surface. To test this hypothesis, we measured the zeta
electrokinetic potential of each strain, which gives an indirect reading of the bacterial
surface charge. We determined that the mutant exhibited approximately a twofold decrease
in zeta potential compared with wild-type bacteria (Fig. 4D), indicating that NaxD is
involved in increasing the charge of the bacterial surface. Taken together, the naxD mutant's
decreased surface charge and increased sensitivity to cationic polymyxin B, which targets
negatively charged lipid A, suggested that NaxD could be required for a modification to
lipid A that alters its charge.
NaxD is required for lipid A modification with galactosamine
In order to determine if NaxD is involved in lipid A modification, we analysed the lipid
fractions of the wild-type and mutant strains using liquid chromatography electro-spray
ionization mass spectrometry (LC-ESI/MS). As mentioned previously, the majority of
Francisella lipid A exists as free lipid A (Vinogradov et al., 2002; Wang et al., 2006). ESI/
MS analysis via direct infusion of wild-type F. novicida free lipid A revealed an anticipated
peak at m/z 1665.22 (Fig. 5A) (Phillips et al., 2004; Wang et al., 2006), while the naxD
mutant lipid A exhibited a peak at m/z 1504.15 (Fig. 5B). Interestingly, this shift
corresponds to the molecular weight of galactosamine, and wild-type Francisella free lipid A
is modified with a galactosamine at the 1 position phosphate (Phillips et al., 2004; Wang et
al., 2006; 2009; Schilling et al., 2007; Shaffer et al., 2007; Kanistanon et al., 2008; Kalhorn
et al., 2009; Song et al., 2009; Soni et al., 2010; Beasley et al., 2012). The absence of the
galactosamine moiety on the free lipid A of the mutant would result in an exposed,
negatively charged phosphate group, which correlates with the decreased surface charge of
the mutant strain (Fig. 4D) (Phillips et al., 2004; Wang et al., 2006).
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To determine why the naxD deletion mutant lacks galactosamine and where NaxD might act
in the lipid A biosynthetic pathway, we measured the presence and quantities of precursor
molecules required for the galactosamine modification. Galactosamine is added to
Francisella free lipid A from undecaprenyl phosphate-galactosamine (undecaprenyl
phosphate-GalN) (Song et al., 2009), a complex of the sugar with a lipid carrier molecule.
Analysis of the wild-type lipid fraction revealed a singly charged peak corresponding to
undecaprenyl phosphate-GalN at m/z 1006.76 (Fig. 5C). However, this glycolipid was not
present in the mutant strain (Fig. 5D). Instead, the mutant exhibited a peak at m/z 1048.79,
corresponding to undecaprenyl phosphate-N-acetylgalactosamine (undecaprenyl phosphate-
GalNAc), the acetylated precursor of undecaprenyl phosphate-GalN (Fig. 5D and E).
Conversely, this acetylated precursor was not detected in the wild-type lipid fraction (Fig.
5C). Taken together, these data show that NaxD is required for deacetylation of
undecaprenyl phosphate-GalNAc and that the absence of this deacetylation event prevents
the galactosamine modification to F. novicida free lipid A.
NaxD is necessary for deacetylation of undecaprenyl phosphate-GalNAc
After MS analysis revealed NaxD was involved in deacetylation of undecaprenyl phosphate-
GalNAc, we set out to determine whether NaxD was directly responsible for this reaction.
First, using a strain in which NaxD was labelled with an 8× histidine tag, we found that
NaxD localizes to the F. novicida membrane fraction (Fig. S4). To determine if NaxD could
deacetylate undecaprenyl phosphate-GalNAc in the membrane, we harvested crude
membrane fractions from either wild-type or mutant strains and incubated them with
synthetic undecaprenyl phosphate-GalNAc. The lipids were extracted from each reaction
and analysed using LC-ESI/MS. For both wild-type and mutant, the substrate peak
(undecaprenyl phosphate-GalNAc, expected m/z 1048.74) was present at time zero (Fig. 6).
After a 5 h incubation, deacetylation of undecaprenyl phosphate-GalNAc was observed in
the wild-type reaction, since a peak consistent with undecaprenyl phosphate-GalN was
detected (Fig. 6A). In contrast, no product peak was observed in the mutant reaction (Fig.
6B). These results showed that NaxD in the membrane fraction was necessary for
undecaprenyl phosphate-GalNAc deacetylation.
To determine if NaxD was responsible for this enzymatic activity, we overexpressed naxD
in E. coli, which does not encode a NaxD homologue, does not synthesize undecaprenyl
phosphate-GalNAc or undecaprenyl phosphate-GalN, and does not modify its lipid A with
galactosamine. We demonstrated that NaxD localized to the E. coli membrane fraction (Fig.
S5), isolated membranes from strains that were transformed with either an empty vector
control or the naxD expression plasmid, and assayed for enzymatic activity as described for
F. novicida above. LC-ESI/MS analysis revealed that there was no deacetylated product
(expected m/z 1006.73) detected for the reactions using a whole-cell lysate from the E. coli
empty vector control strain (Fig. 7A) or with the soluble fraction from E. coli expressing
naxD (Fig. 7B). However, the deacetylated product, undecaprenyl phosphate-GalN, was
detected in assays that contained the membrane fraction from E. coli expressing NaxD (Fig.
7C). Together, these results using membrane fractions from F. novicida and E. coli
respectively demonstrate that NaxD is necessary and suggest that it is sufficient for
deacetylation of undecaprenyl phosphate-GalNAc.
The NaxD orthologue in F. tularensis is required for lipid A modification and virulence
The NaxD orthologue from human pathogenic F. tularensis, FTT_0453, retains 99% amino
acid identity with F. novicida NaxD (Fig. 2A). In order to ascertain if NaxD function is
conserved in F. tularensis, we generated a FTT_0453 (naxD) deletion mutant in strain
SchuS4. LC-ESI/MS analysis of wild-type F. tularensis free lipid A revealed the m/z
1665.21 peak that corresponds to Fran-cisella lipid A modified with galactosamine (Fig.
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8A), although this species was not detected in the mutant. Instead, the naxD mutant
displayed a peak at m/z 1504.13 that corresponds to lipid A without galactosamine (Fig.
8B). This demonstrates the conserved role of NaxD in lipid A modification in highly
virulent F. tularensis.
Next we tested the functional role of F. tularensis NaxD in polymyxin B resistance,
intracellular replication and in vivo survival. The naxD deletion mutant displayed an
increased susceptibility to polymyxin B as compared with wild-type (Fig. 8C). Given that F.
tularensis is a virulent human pathogen, we wanted to determine the importance of NaxD
function during infection of human cells. Indeed, we observed a severe defect in replication
of the naxD deletion mutant compared with wild-type F. tularensis 24 h after infection of
human THP-1 macrophage-like cells (Fig. 8D). In addition, similar to the F. novicida naxD
mutant (Fig. 3B), the F. tularensis naxD deletion mutant was unable to proliferate in primary
murine BMM (Fig. S3). Importantly, NaxD was also required for replication in mice, since
48 h after subcutaneous infection, wild-type F. tularensis was recovered at a level 2.5 logs
higher in the spleen of mice (Fig. 8E) and nearly 1.5 logs higher in the liver than the mutant
strain (Fig. 8F). These data show that NaxD function is conserved in human pathogenic F.
tularensis, in which it is required for the addition of galactosamine to free lipid A and is
required for resistance to the cationic antimicrobial peptide polymyxin B, replication within
human cells and virulence in mice.
Conserved role of the NaxD homologue in Bordetella bronchiseptica
Given that the YdjC superfamily of proteins is conserved among many virulent bacteria, we
wanted to determine if a NaxD homologue from a different pathogen shared a similar
function in lipid A modification. To test this, we generated a B. bronchiseptica deletion
mutant lacking the gene encoding the NaxD homologue BB4267 (Fig. 2). B. bronchiseptica
is a Gram-negative bacterium that colonizes mammalian respiratory tracts and is considered
a primary pathogen of domestic animals such as dogs, cats, rabbits and pigs, but can also
establish chronic infections in immunocompromised humans (Egberink et al., 2009). Lipid
A from this pathogen has two phosphate groups that are known to be modified with
glucosamine, a stereoisomer of galactosamine (Tirsoaga et al., 2007; Marr et al., 2008;
Basheer et al., 2011). Although BB4267 is nearly 100 amino acids larger than NaxD, the
majority of the protein is comprised of the YdjC superfamily domain, including the
conserved putative active-site residues, which suggests conserved function (Fig. 2B).
Indeed, LC-ESI/MS analysis of the wild-type lipid fractions revealed a doubly charged lipid
A peak at m/z 1072.70 that corresponds to lipid A with glucosamine modifications at both
the 4′ and 1 position phosphates (Fig. 9A). This peak was absent in the mutant fractions,
which instead displayed a doubly charged peak at m/z 911.64, corresponding to the lipid A
molecule missing both glucosamine modifications (Fig. 9B). These data show that the NaxD
homologue BB4267, like NaxD in Francisella, is required for the modification of lipid A
phosphates with hexosamine sugars.
Similar to the addition of galactosamine to Francisella lipid A, the modification of B.
bronchiseptica lipid A with glucosamine requires the deacetylation of undecaprenyl
phosphate-N-acetylglucosamine (undecaprenyl phosphate-GlcNAc) to form undecaprenyl
phosphate-glucosamine (undecaprenyl phosphate-GlcN). LC-ESI/MS from the lipid fraction
of the wild-type strain showed a singly charged peak at m/z 1006.85, corresponding to
undecaprenyl phosphate-GlcN (Fig. 9C). In contrast, the bb4267 mutant displayed a peak at
m/z 1048.88, corresponding to undecaprenyl phosphate-GlcNAc (Fig. 9D), which was
undetectable in the wild-type. This demonstrates that, similar to NaxD function in
Francisella, BB4267 is required for a deacetylation reaction in B. bronchiseptica. To test the
functional relevance of the lipid A modification with glucosamine, we measured the
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polymyxin B sensitivity of the wild-type and mutant strains and found that the bb4267
mutant exhibited a dose-dependent increase in susceptibility to polymyxin B as compared
with wild-type (Fig. 9E). These data confirm that the function of NaxD is conserved among
multiple Gram-negative pathogens.
Discussion
Using in vivo negative selection (Weiss et al., 2007) and intramacrophage replication
(Llewellyn et al., 2011) screens, we have recently identified NaxD as an important virulence
factor of Francisella. Here we have extended those findings by showing that this member of
the YdjC protein superfamily is a deacetylase that is required for lipid A modifications that
render bacteria more resistant to killing by the cationic antimicrobial peptide polymyxin B.
Given our findings that the B. bronchiseptica NaxD homologue is also required for lipid A
modification, this report suggests that NaxD/YdjC proteins are likely to have an important
role in the pathogenesis of other virulent Gram-negative bacteria.
This work contributes to a greater understanding of the mechanisms by which Francisella is
able to so effectively evade killing by antimicrobial peptides compared with other Gram-
negative pathogens (Ishimoto et al., 2006; Mohapatra et al., 2007). For example, Francisella
is nearly 1000× more resistant to polymyxin B than E. coli (Mohapatra et al., 2007).
Because polymyxin B is known to bind Gram-negative lipid A, it is interesting that the
majority of the exposed surface of the Francisella outer membrane consists of free lipid A
(Zhao and Raetz, 2010). To our knowledge, Francisella is the only Gram-negative pathogen
shown to exhibit this sort of unique outer membrane composition. Mutants that lack the
galactosamine modification on free lipid A have an exposed phosphate at the 1 position
(Phillips et al., 2004; Bina et al., 2006; Schilling et al., 2007; Shaffer et al., 2007;
Kanistanon et al., 2008; Kalhorn et al., 2009; Song et al., 2009; Wang et al., 2009; Soni et
al., 2010; Beasley et al., 2012), significantly altering the charge and likely the topography of
the majority of the outer leaflet of the outer membrane. Interestingly, the small percentage of
lipid A that is part of complete LPS lacks the 1 position phosphate and, therefore, the
galactosamine modification as well (Zhao and Raetz, 2010). It is not clear why Francisella
produces such a large amount of lipid A without O-antigen, given that O-antigen is critical
for virulence (Sandstrom et al., 1988; Sorokin et al., 1996; Clay et al., 2008). However,
since the majority of Francisella's outer membrane is composed of free lipid A, it is intuitive
that the galactosamine modification to this moiety would be critical in resistance to host
stresses, similar to the importance of modifications to complete LPS in other bacteria (Wang
and Quinn, 2010). Indeed, given that this modification is important for resistance to
polymyxin B, replication in macrophages, and during in vivo infection, it likely contributes
to Francisella resistance to host cationic antimicrobial peptides such as cathelicidins,
defensins and ubiquicidin (Weiss et al., 2007; Kanistanon et al., 2008; Flannagan et al.,
2009; Llewellyn et al., 2011). Future work will aim to elucidate whether there are
advantages conferred by the novel cell surface component free lipid A, e.g. whether free
lipid A promotes enhanced resistance to host antimicrobials compared with full LPS.
The Gram-negative pathogen B. bronchiseptica has been shown to express lipid A species
that have one or both phosphates modified with glucosamine, a stereoisomer of
galactosamine (Tirsoaga et al., 2007; Marr et al., 2008; Basheer et al., 2011). Like
galactosamine, addition of glucosamine neutralizes the negative charge of lipid A
phosphates (Marr et al., 2008). In this study we show that the B. bronchiseptica NaxD
homologue BB4267 is required for the glucosamine modification of lipid A phosphates and
specifically is necessary for the deacetylation of undecaprenyl phosphate-N-
acetylglucosamine. Similar to the Francisella galactosamine modification, we show that this
glucosamine modification is important for resistance to the lipid A-binding cationic
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antimicrobial peptide polymyxin B. While no bacteria other than Francisella species have
been reported to utilize free lipid A, our B. bronchiseptica data indicate that NaxD
homologues could be involved in modifying the lipid A component of complete LPS of
other Gram-negative pathogens.
This study has generated new insight into Francisella pathogenesis and lipid A biosynthesis
as well as the function of YdjC superfamily proteins. Significantly, this study has broad
implications for host–pathogen interactions of other highly virulent NaxD homologue-
encoding Gram-negative bacteria, particularly intracellular pathogens such as B. abortus, L.
pneumophila and C. burnetii. Future studies on the role of this family of proteins will likely
further illuminate the virulence mechanisms of other NaxD homologue-encoding pathogenic
bacteria.
Experimental procedures
Bacterial strains and growth conditions
Wild-type F. novicida strain U112 and a previously described mglA point mutant, GB2
(Baron and Nano, 1998), were a generous gift from Dr Denise Monack (Stanford University,
Stanford, CA). These strains, the naxD deletion mutant and the naxD complemented strain
were grown at 37°C on a rolling drum in tryptic soy broth (TSB; Difco/BD, Sparks, MD)
supplemented with 0.02% L-cysteine (Sigma-Aldrich, St. Louis, MO). F. novicida was
plated for colony-forming units (cfu) on tryptic soy agar (TSA; Difco/BD) and
supplemented with 0.01% L-cysteine, with the exception of bacteria from mouse
experiments, which were plated on modified Mueller Hinton (mMH) agar plates (Difco/BD)
supplemented with 0.025% ferric pyrophosphate (Sigma-Aldrich), 0.1% glucose (Sigma-
Aldrich) and 0.01% L-cysteine. When appropriate, kanamycin (Fisher Scientific, Fair Lawn,
NJ) was added to media at a concentration of 30 μg ml-1. F. tularensis strains were grown in
mMH broth or on Brain Heart Infusion (BHI) agar (BHI supplemented with 50 μg ml−1
haemin, 1.4% agar (w/v) and 1% (v/v) IsoVitalex (BBL, Cockeysville, MD). Counter
selection for resolution of F. tularensis FTT0453 deletion plasmid co-integrants was
performed on cysteine heart agar containing 5% sucrose. Kanamycin was added to the plates
when necessary at 10 μg ml−1 for F. tularensis. B. bronchiseptica wild-type strain RB50, the
bb4267 deletion mutant and the bb4267 complemented strain were grown under similar
conditions as F. novicida, except using Stainer-Scholte broth supplemented with nicotinic
acid, glutathione and ascorbic acid as previously described (Hulbert and Cotter, 2009), or
Bordet-Gengou blood agar plates (Remel, Lenexa, KS). When appropriate, streptomycin
(Fisher Scientific) and kanamycin were added at concentrations of 25 μg ml−1 and 50 μg
ml−1 respectively.
Mutagenesis and complementation
To generate the naxD deletion mutant in F. novicida, PCR was used to amplify flanking
DNA regions upstream and downstream of the gene of interest. A kanamycin resistance
cassette was sewn in between these flanking regions using overlapping PCR reactions. The
final linear PCR product was then gel purified and transformed into chemically competent
wild-type strain U112 as previously described (Anthony et al., 1991). The primers used to
create the kanamycin-resistant deletion mutant contained FRT sites flanking the kanamycin
resistance cassette, which allowed a clean deletion of each mutant to be made using the
plasmid pFFlp encoding the Flp-recombinase as previously described (Gallagher et al.,
2008). A construct for the complementation of the mutant was generated by overlapping
PCR using PCR-amplified fragments of the wild-type gene of interest, upstream and
downstream flanking regions, and a kanamycin resistance cassette. These constructs were
then transformed into the chemically competent naxD clean deletion mutant. Verification of
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allelic replacement in the mutant and complemented strains was performed using check
primers in PCR reactions on purified genomic DNA from each strain. PCR products of the
correct size were subsequently sequenced (MWG Operon, Huntsville, AL) for final
verification of allelic replacement. PCR constructs for F. tularensis mutagenesis were
amplified as for F. novicida and then cloned into plasmid pXB186 containing a kanamycin
resistance cassette and the sacB counter-selectable marker (making plasmid pΔFTT0453).
To generate the FTT0453 deletion mutant, the deletion plasmid was introduced by
electroporation into electrocompetent F. tularensis SchuS4. Electrocompetent cells were
prepared on the day of the transformation as described in the supplemental experimental
procedures. The resulting clones were screened by PCR for the FTT0453 deletion. To
generate the B. bronchiseptica bb4267 deletion mutant, linear PCR deletion constructs were
amplified as described above for F. novicida. This bb4267-deleting fragment was cloned
into the Bordetella allelic exchange plasmid pSS4245. The resulting plasmid was then
transformed into wild-type B. bronchiseptica strain RB50, following procedures described
previously (Inatsuka et al., 2010). The loss of bb4267 was confirmed by PCR and
subsequent enzymatic digestions. To generate the complementation plasmid, the two
external primers used to produce the bb4267-deleting fragment were employed and this
complementing fragment was cloned into pUC18-Mini-TN7 plasmid that has a Tn7
integration sequence, which, along with a helper plasmid pTNS3, was mated into the
deletion strain via tri-parental mating (Choi et al., 2005) to generate the complemented
strain. All primers and plasmids used in this study are listed in Table S1.
Antimicrobial assays
The antimicrobial peptide polymyxin B (USB, Cleveland, OH) was dissolved in peptide
buffer (0.01% acetic acid, 0.2% BSA) and then serially diluted in the same buffer to desired
concentrations. The detergents sodium-dodecyl-sulphate (SDS; Fisher Scientific) and Triton
X-100 (Fisher Scientific) were serially diluted in 25% TSB. Overnight cultures of bacteria
were diluted to 1 × 107 cfu ml−1 in 25% TSB. Ninety microlitres of diluted cultures were
then added to 96-well plates containing 10 ml of the appropriate antimicrobial. Plates were
incubated at 37°C on shaking platforms for 6 h. Cultures were then serially diluted and
plated to enumerate cfu. F. tularensis antimicrobial susceptibility was determined by the
gradient agar plate method as previously described (Szybalski and Bryson, 1952; Bina et al.,
2006; 2008). Briefly, 35 ml of BHI-chocolate agar (without polymyxin B) was poured into a
square Petri dish and allowed to solidify as a wedge by elevating one side of the plate. After
the agar solidified, 35 ml of BHI-chocolate agar containing polymyxin B at 2 mg ml−1 was
added to the levelled plate and allowed to solidify. Theses plates were inoculated with
overnight mMH broth cultures of each respective strain and incubated at 37°C for 2 days
when the length of growth along the polymyxin B gradient was recorded. The gradient agar
plate tests were performed a minimum of three times and representative results are
presented.
Zeta electrokinetic potential
Overnight cultures of bacteria were subcultured and grown to OD600 = 1.0. The bacteria
were then pelleted (10 000 g, 3 min) and resuspended at a 5× concentration in 20 mM
potassium chloride. Twenty microlitres of the concentrated bacteria were added to 3.2 ml of
20 mM potassium chloride in the zeta potential electrokinetic cuvette from Brookhaven
Instruments Corporation (BIC, Holtsville, NY). The bacterial sizes and zeta electrokinetic
potentials were measured using the 90Plus size and zeta potential analyser (BIC). Data were
analysed using BIC Zeta Potential Analyser Software Version 5.20, which takes into
account the size of the bacteria when calculating the zeta potential.
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RAW264.7 murine macrophages (ATCC, Manassas, VA) were cultured in Dulbecco's
modified Eagle's medium (high glucose, L-glutamine; DMEM; Lonza, Walkersville, MD)
supplemented with 10% heat-inactivated fetal calf serum (FCS; HyClone, Logan, UT). Bone
marrow-derived macrophages (BMM) were isolated from wild-type C57BL/6 mice and
cultured as described previously (Schaible and Kaufmann, 2002) in DMEM supplemented
with 10% heat-inactivated FCS and 10% macrophage colony-stimulating factor (M-CSF)-
conditioned medium (collected from M-CSF-producing L929 cells). THP-1 monocyte-like
cells (ATCC) were cultured in RPMI (Lonza) with 10% heat-inactivated fetal calf serum
(HyClone). Macrophages were incubated before and during infection at 37°C with 5% CO2.
Macrophage infections
RAW264.7 macrophages were seeded in 24-well plates at 5 × 105 cells per well and
incubated overnight. The following day, overnight cultures of the indicated strains were
pelleted (10 000 g, 3 min) and resuspended in DMEM/10% FCS. After removal of the
overnight media, the macrophages were infected with bacteria at an moi of 20:1 (bacteria to
macrophage), centrifuged for 15 min at 900 g, and then incubated for 30 min. Next, the
macrophages were washed twice with warm DMEM and then incubated in DMEM/10%
FCS with 10 μg ml−1 gentamicin. At 30 min and 24 h post infection, the macrophages were
washed twice and then lysed with 1% saponin in phosphate-buffered saline (PBS).
Macrophage lysates were serially diluted and plated on mMH agar, the resulting cfu were
enumerated and the fold replication of each strain was determined. The same protocol as
above was followed for the BMM infections with the following alterations: 3 × 105 BMM
were plated per well, DMEM/10% FCS/10% M-CSF was used throughout, and the final
time point was 6 h instead of 24 h. The difference in time point was due to the fact that F.
novicida triggers inflammatory mediated cell death in BMM (Mariathasan et al., 2005).
Therefore, bacterial replication was measured at 6 h post infection to minimize loss of
bacterial counts as a consequence of the host cell death response. It is likely that we did not
observe this early cell death in RAW264.7 macrophages because this cell line is known to
be deficient in ASC/caspase-1 inflammasome-mediated cell death (Pelegrin et al., 2008).
For F. tularensis experiments, THP-1 cells or BMM were seeded into 24-well tissue culture
plates (3 × 105 cells per well) in a total volume of 1 ml of culture medium. THP-1 cells were
treated with 200 nM phorbol 12-myristate 13-acetate (PMA) immediately after cells were
plated. The cells were infected 24 h later with the indicated strains at an moi of 50:1 bacteria
to macrophage. Fifty micrograms per millilitre of gentamicin was added 2 h later to kill any
remaining extracellular bacteria. At 2 or 24 h after infection, wells were washed twice with
PBS, lysed, and then bacteria were enumerated by dilution plating in duplicate using an IUL
Eddy Jet Spiral plater and a Flash and Go automated colony counter (Neutec Group,
Farmingdale, NY).
Mice
For F. novicida experiments, female C57BL/6 mice (Jackson Laboratory, Bar Harbor, ME)
between 7 and 10 weeks of age were kept under specific pathogen-free conditions in filter-
top cages at Emory University and provided with sterile food and water ad libitum.
Experimental studies were performed in accordance with the Emory University Institutional
Animal Care and Use Committee (IACUC) guidelines. For F. tularensis experiments,
C57BL/6 mice were purchased from Charles River Laboratories. Mice were age-matched
and used between 7 and 10 weeks of age. Mice were housed in sealed Allentown caging and
HEPA-filtered cage racks with food and water ad libitum. All experimental protocols were
reviewed and approved by the University of Tennessee Health Science Center IACUC.
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For competition experiments, mice were inoculated subcutaneously with a 1:1 ratio of
kanamycin-resistant deletion mutant and kanamycin-sensitive wild-type F. novicida for a
total of 2 × 105 cfu in 50 μl of sterile PBS. After 48 h, the mice were sacrificed and the
spleen, liver and skin at the site of infection were harvested, homogenized, plated for cfu on
MH plates with and without kanamycin, and then incubated overnight at 37°C. Competitive
index (CI) values were determined using the formula: (cfu mutant output/cfu WT output)/
(cfu mutant input/cfu WT input). For survival experiments, mice were infected
subcutaneously with 2 × 105 cfu of either the deletion mutant or wild-type strain in 50 μl of
sterile PBS and then monitored for signs of illness and sacrificed if they appeared moribund.
For F. tularensis infection experiments, mice were challenged subcutaneously with 50 cfu in
100 μl of sterile PBS. All procedures were performed under BSL3 containment according to
standard operating procedures that have been fully vetted by the UTHSC Committee On
Biocontainment and Restricted Entities (COBRE). Spleens, livers and lungs of challenged
mice were homogenized with a disposable tissue homogenizer in 1 ml of sterile PBS and
then 0.25 ml disruption buffer (2.5% saponin, 15% BSA, in PBS) was added with light
vortexing. Appropriate dilutions of each sample were then plated in duplicate using an Eddy
Jet spiral plater on mMH agar plates supplemented with 5% calf serum and incubated at
37°C for 48–72 h. Colonies were counted using a Flash & Go automated colony counter.
Preparation of total lipids
Overnight cultures of F. novicida U112 wild-type or naxD mutant strains were subcultured
to OD600 = 0.02 and grown at 37°C in TSB supplemented with L-cysteine until the OD600 =
1.0. The cells were collected by centrifugation (5000 g, 20 min) and washed with PBS. The
cell pellets were resuspended in a single-phase Bligh-Dyer mixture (Bligh and Dyer, 1959)
consisting of chloroform, methanol and water (1:2:0.8, v/v), incubated at room temperature
for 60 min, and centrifuged (10 000 g, 20 min) to remove insoluble debris. The supernatant
was converted to a two-phase Bligh-Dyer system by adding chloroform and water to
generate a mixture consisting of chloroform, methanol and water (2:2:1.8, v/v). The two
phases of Bligh-Dyer system were separated under centrifugation and the lower phase was
dried by rotary evaporation and under a stream of nitrogen. The total lipids were analysed
using thin-layer chromatography (TLC) and LC-ESI/MS. The TLC plate was developed
using the solvent chloroform, methanol, pyridine, acetic acid and water (25:10:5:4:3, v/v).
Lipids were detected by spraying 10% of sulphuric acid in ethanol and charring at 300°C.
Negative ion mode electrospray ionization (ESI) mass spectrometry (MS) and MS/MS
analysis
All ESI/MS and MS/MS spectra were acquired on a QSTAR XL quadrupole time-of-flight
tandem mass spectrometer (Applied Biosystems, Foster City, CA) equipped with an ESI
source. Lipid A samples were dissolved in chloroform and methanol (2:1, v/v) containing
1% piperidine and subjected to ESI/MS in the negative ion mode via direct infusion (Garrett
and Yost, 2006; Guan et al., 2007; Wang et al., 2009). Nitrogen was used as the collision gas
for MS/MS experiments (Garrett and Yost, 2006; Guan et al., 2007; Wang et al., 2009). Data
acquisition and analysis were performed using the instrument's Analyst QS software.
Liquid chromatography/mass spectrometry (LC/MS)
LC/MS of lipids was performed using a Shimadzu LC system (comprising a solvent
degasser, two LC-10A pumps and an SCL-10A system controller) coupled to a QSTAR XL
quadrupole time-of-flight tandem mass spectrometer (as above). LC was performed at a flow
rate of 200 μl min−1 with a linear gradient as follows: 100% mobile phase A was held
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isocratically for 2 min and then linearly increased to 100% mobile phase B over 14 min and
held at 100% B for 4 min. Mobile phase A consisted of methanol/acetonitrile/aqueous 1 mM
ammonium acetate (60:20:20, v/v/v). Mobile phase B consisted of 100% ethanol containing
1 mM ammonium acetate. A Zorbax SB-C8 reversed-phase column (5 m, 2.1 × 50 mm) was
obtained from Agilent (Palo Alto, CA). The postcolumn splitter diverted ~ 10% of the LC
flow to the ESI source of the mass spectrometer.
Membrane fractionation
Fifty millilitres of F. novicida strains were harvested at OD600 = 1.0 by centrifugation for 20
min at 5000 g at 4°C. Cell pellets were washed with 50 mM K + HEPES, pH 7.5, resus-
pended in 5 ml of the same buffer and passed through a French pressure cell at 18 000 p.s.i.
Unbroken cells were then removed by centrifugation at 10 000 g for 20 min at 4°C.
Membrane fractions were pelleted from whole-cell lysates by ultracentrifugation at 200 000
g for 2 h at 4°C. F. novicida fractionation and protein localization were verified using
Western blotting (see supplemental experimental procedures). For E. coli, fractions were
prepared similarly with the following exceptions: E. coli C41 (DE3) strains transformed
with the empty vector or vector encoding naxD were grown in LB broth (1% tryptone, 0.5%
yeast extract and 1% NaCl) with 100 μg ml−1 ampicillin and were induced using 1 mM
IPTG when cell density reached OD600 = 0.8, then harvested when the OD600 = 2.0. NaxD
protein expression was analysed using 12% SDS-PAGE gel and Coomassie staining.
Undecaprenyl phosphate-GalNAc deacetylase assay
These assays measured the deacetylase activity of proteins from the F. novicida wild-type or
naxD mutant membrane fractions, whole-cell lysate of E. coli transformed with the empty
vector, and the membrane and cytosolic fractions of E. coli transformed with vector
encoding naxD (grown under inducing conditions). The 100 μl reaction mixture included 50
μg ml−1 protein from the bacterial fractions, 4.0 μM synthesized undecaprenyl phosphate-
GalNAc (Song et al., 2009), 1 mM MnCl2, 150 mM KCl, 1.0 mg ml−1 BSA, 0.1% Triton
X-100 and 50 mM HEPES (pH 7.5) and was incubated at 30°C. A 20 μl sample was
removed at 0 and 5 h for F. novicida and 0 and 1 h for E. coli. Samples were converted to a
two-phase Bligh-Dyer system by the addition of chloroform and methanol. After
centrifugation, the lower phase was dried under nitrogen and analysed using LC-ESI/MS.
Statistical analysis
All macrophage replication, single infection, killing assay and zeta potential data were
analysed for significance using the unpaired Student's t-test. For zeta potential, values
beyond three standard deviations of the mean were excluded as outliers. The CI values from
the mouse competition experiments were analysed with the one-sample Student's t-test and
compared with 1. The mouse survival infection data were analysed for significance using the
Gehan–Breslow–Wilcoxon test.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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E. coli and Francisella LPS and lipid A structures. Structures of (A) E. coli LPS, (B)
complete LPS from Francisella species and (C) ‘free’ lipid A of Francisella species are
compared. (A, B) O-antigen (O Ag), core sugars (Core) and the specific core sugar Kdo
(Kdo) are indicated. For all structures, lipid A backbone disaccharides are highlighted in
blue and acyl chains are represented in black with numbers denoting length. E. coli lipid A
4′ and 1 position phosphate groups (missing from the lipid A of complete Francisella LPS)
are highlighted in red. Unlike the lipid A component of complete Francisella LPS,
Francisella free lipid A includes a phosphate modified with galactosamine at the 1 position
(highlighted in green).
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NaxD is a member of the YdjC superfamily. The amino acid sequences of F. novicida and F.
tularensis NaxD (FTN_0544 and FTT_0453 respectively) were aligned with YdjC
superfamily proteins from Thermus thermophilus (TTHB029), Bordetella bronchiseptica
(BB4267), Legionella pneumophila (lp12_2472), Brucella abortus (BAbS19_II01260) and
Coxiella burnetii (CBU_0580) using CLUSTALO (http://www.ebi.ac.uk/Tools/msa/clustalo/).
A. The per cent amino acid identity and similarity to F. novicida NaxD are shown. Proteins
in bold and highlighted in red are described in this manuscript.
B. Amino acids surrounding putative active-site residues are shown and numbers indicate
their position in the sequence. Highlighting indicates conserved putative active-site residues
(red, asterisk), identical (black) and similar (grey) residues.
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NaxD is required for replication in murine macrophages and mice.
A and B. (A) RAW264.7 or (B) primary murine bone marrow-derived macrophages (BMM)
were infected with a 20:1 moi of wild-type F. novicida (WT), the mglA mutant (mglA), the
naxD deletion strain (ΔnaxD) or the complemented strain (comp). Colony-forming units
from lysates 30 min post infection were compared with those from (A) 24 or (B) 6 h post
infection to determine fold intracellular replication (n = 3 biological replicates).
C. Mice were subcutaneously infected with a 1:1 mixture of 105 cfu each of wild-type and
ΔnaxD (red) or wild-type and the complemented strain (grey). Forty-eight hours after
infection, organs were harvested, cfu enumerated and the competitive index (CI) calculated
for the skin at the site of infection, spleen and liver. CI = (cfu mutant output/cfu WT output)/
(cfu mutant input/cfu WT input). Bars represent the geometric mean CI values from each
group of mice (n = 5 mice). CI values below 1 (dashed line) indicate attenuation of the
mutant strain.
D. Mice were subcutaneously infected with 2 × 107 cfu of either wild-type or ΔnaxD and
sacrificed if they appeared moribund (n = 4 mice).
In (A) and (B), bars represent the average and error bars represent the standard deviation of
three biological replicates from one experiment. Data shown in all panels are representative
of at least three independent experiments. Asterisks indicate significance as compared with
wild-type (A, B, D) or compared with 1 (C). **P < 0.005, ***P < 0.0005.
Llewellyn et al. Page 18














NaxD is involved in resistance to cationic antimicrobials and alteration of bacterial surface
charge.
A–C. Wild-type F. novicida (WT), the naxD deletion mutant (ΔnaxD) or the complemented
strain (comp) were incubated with the indicated concentrations of (A) polymyxin B, (B)
SDS or (C) Triton X-100 for 6 h. Cultures were then serially diluted and plated for cfu (n =
3 biological replicates).
D. The zeta potential of wild-type and ΔnaxD was measured (n = 10 technical replicates)
and the results of three independent experiments were combined for statistical analysis.
In (A)–(C), bars represent the average and error bars represent the standard deviation of
three biological replicates from one experiment. Data shown are representative of at least
three independent experiments. Asterisks indicate significance as compared with wild-type.
*P < 0.05, **P < 0.005, ***P < 0.0005.
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NaxD is required for the galactosamine modification of F. novicida free lipid A.
A–D. Total lipids were extracted from (A, C) wild-type F. novicida (WT) and (B, D) naxD
mutant (ΔnaxD) strains in mid-log phase and (A, B) free lipid A, (C, D) undecaprenyl
phosphate-N-acetylgalactosamine (GalNAc), and undecaprenyl phosphate-galactosamine
(GalN) were analysed by ESI/MS in negative ion mode via direct infusion.
E. A schematic for the deacetylation of undecaprenyl phosphate-GalNAc (expected m/z =
1048.74) to undecaprenyl phosphate-GalN (expected m/z = 1006.73) is shown.
(A, E) Galactosamine is highlighted in green and (E) the acetyl group is highlighted in red.
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NaxD is necessary for deacetylation of undecaprenyl phosphate-N-acetylgalactosamine.
Deacetylase activity assays using synthesized undecaprenyl phosphate-N-
acetylgalactosamine (GalNAc) and (A) 0.5 mg ml−1 F. novicida wild-type (WT) membrane
fraction or (B) F. novicida naxD mutant (ΔnaxD) membrane fraction were incubated at 30°C
for the indicated times and then analysed using LC-ESI/MS in negative ion mode.
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NaxD is required for deacetylation of undecaprenyl phosphate-N-acetylgalactosamine when
exogenously expressed in E. coli. Deacetylase activity assays using synthesized
undecaprenyl phosphate-N-acetylgalactosamine (GalNAc) and (A) whole-cell lysate from E.
coli with an empty vector, (B) the soluble fraction from E. coli expressing naxD, or (C) the
membrane fraction from E. coli expressing naxD were incubated at 30°C for the indicated
times and then analysed using LC-ESI/MS in negative ion mode.
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NaxD function is conserved in human pathogenic F. tularensis.
A and B. Total lipids were extracted from (A) wild-type F. tularensis and (B) the ΔnaxD
strain in mid-log phase and lipid A composition was analysed by LC-ESI/MS. (A)
Galactosamine is highlighted in green.
C. The distance of growth of wild-type or ΔnaxD along a 0–2 mg ml−1 gradient of
polymyxin B was measured (n = 3 biological replicates).
D. Human PMA-differentiated THP-1 macrophage-like cells were infected with either wild-
type F. tularensis (WT) or the naxD deletion mutant (ΔnaxD) at a 50:1 moi. Colony-forming
units recovered from macrophages lysed 24 h after infection were compared with cfu
recovered at 2 h post infection to calculate fold replication (n = 3 biological replicates).
E and F. Mice were subcutaneously infected with 50 cfu of either wild-type or ΔnaxD and
48 h after infection, organs were harvested and plated and cfu were enumerated for the (E)
spleen and (F) liver (n = 5 mice).
In (C) and (D), bars represent the average and error bars represent the standard deviation of
three biological replicates from one experiment. Data shown in (C)–(F) are representative of
at least three independent experiments. Asterisks indicate significance as compared with
wild-type. *P < 0.05, ***P < 0.0005.
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Conserved role of the Bordetella bronchiseptica NaxD homologue in lipid A modification.
A–D. Total lipids were extracted from wild-type (WT) and naxD homologue mutant (mut)
strains of B. bronchiseptica in mid-log phase and (A, B) lipid A, (C) undecaprenyl
phosphate-glucosamine (GlcN) and (D) undecaprenyl phosphate-N-acetylglucosamine
(GlcNAc) analysed by LC-ESI/MS. In (A), glucosamine groups are highlighted in green.
E. WT, mut or the complemented strain (comp) were incubated with the indicated
concentrations of polymyxin B for 6 h and cfu were enumerated (n = 3 biological
replicates). Bars represent the average and error bars represent the standard deviation of
three biological replicates from one experiment. Data shown are representative of at least
three independent experiments. Asterisks indicate significance as compared with wild-type.
**P < 0.005.
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